연구
교육
로그인
KR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
Division of Molecular Oncology
Benedetta Apollonio has not added Biography.
If you are Benedetta Apollonio and would like to personalize this page please email our Author Liaison for assistance.
Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy.
Blood Jul, 2008 | Pubmed ID: 18292287
Monoclonal B lymphocytosis in the general population.
Leukemia & lymphoma Mar, 2009 | Pubmed ID: 19347732
A novel Rag2-/-gammac-/--xenograft model of human CLL.
Blood Feb, 2010 | Pubmed ID: 20018917
Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models.
Blood Jul, 2011 | Pubmed ID: 21652674
In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors.
Clinical cancer research : an official journal of the American Association for Cancer Research Jan, 2013 | Pubmed ID: 23224401
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.
Blood Mar, 2013 | Pubmed ID: 23325840
Targeting B-cell anergy in chronic lymphocytic leukemia.
Blood May, 2013 | Pubmed ID: 23460614
SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders.
Haematologica Aug, 2014 | Pubmed ID: 24859880
IRCCS, San Raffaele Scientific Institute
King's College London
Benedetta Apollonio1,2,
Maria Teresa Sabrina Bertilaccio1,
Umberto Restuccia3,
Pamela Ranghetti1,
Federica Barbaglio1,
Paolo Ghia1,4,
Federico Caligaris-Cappio1,4,
Cristina Scielzo1
1Division of Molecular Oncology, IRCCS, San Raffaele Scientific Institute,
2Department of Haemato-Oncology, King's College London,
3, IFOM, FIRC Institute of Molecular Oncology,
4, Università Vita-Salute San Raffaele
개인 정보 보호
이용 약관
정책
연락처
사서에게 추천하기
JoVE 뉴스레터
JoVE Journal
연구 방법 컬렉션
JoVE Encyclopedia of Experiments
아카이브
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
교수 리소스 센터
저자
사서
액세스
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유